Odor identification as a biomarker of preclinical AD in older adults at risk
Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS, PREVENT-AD Research Group.. Neurology, 2017-06-28
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To assess odor identification (OI) as an indicator of presymptomatic Alzheimer disease (AD) pathogenesis in cognitively normal aging individuals at increased risk of AD dementia. Methods In 274 members of the PREVENT-AD cohort of healthy aging persons with a parental or multiple-sibling history of AD dementia, we assessed the cross-sectional association of OI with potential indicators of presymptomatic AD. Some 101 participants donated CSF, thus enabling assessment of AD pathology with the biomarkers total tau (t-tau), phospho-tau (P 181 -tau), and their ratios with β-amyloid (Aβ 1-42 ). Adjusted analyses considered age, cognition, APOE ε4 status, education, and sex as covariates. We measured OI using the University of Pennsylvania Smell Identification Test and cognitive performance using the Repeatable Battery for Assessment of Neuropsychological Status. Standard kits provided assays of the AD biomarkers. Analyses used robust-fit linear regression models. Results Reduced OI was associated with lower cognitive score and older age, as well as increased ratios of CSF t-tau and P 181 -tau to Aβ 1-42 (all p 1-42 alone except in APOE ε4 carriers having lowest-quartile Aβ 1-42 levels. Conclusions These findings from healthy high-risk older individuals suggest that OI reflects degree of preclinical AD pathology, while its relationships with age and cognition result from the association of these latter variables with such pathology. Diminished OI may be a practical and affordable biomarker of AD pathology.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 101 participants. In cognitively normal older adults with a family history of Alzheimer's dementia, poorer ability to identify odors was associated with lower cognitive scores and with higher ratios of CSF tau to amyloid-beta. This cross-sectional finding suggests odor identification might reflect preclinical Alzheimer's pathology, but it does not show that testing smell can prevent or treat the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lafaille-Magnan, M. E., Poirier, J., Etienne, P., Tremblay-Mercier, J., Frenette, J., Rosa-Neto, P., et al. (2017). Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology. https://doi.org/10.1212/wnl.0000000000004159
Vancouver
Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, et al. Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology. 2017. doi:10.1212/wnl.0000000000004159. PMID: 28659431.
BibTeX
@article{lafaillemagnan2017-28659431,
author = {Lafaille-Magnan, M. E. and Poirier, J. and Etienne, P. and Tremblay-Mercier, J. and Frenette, J. and Rosa-Neto, P. and Breitner, J. C. S. and {PREVENT-AD Research Group}},
title = {{Odor identification as a biomarker of preclinical AD in older adults at risk}},
journal = {Neurology},
year = {2017},
doi = {10.1212/wnl.0000000000004159},
pmid = {28659431},
url = {https://doi.org/10.1212/wnl.0000000000004159}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Objective To assess odor identification (OI) as an indicator of presymptomatic Alzheimer disease (AD) pathogenesis in cognitively normal aging individuals at increased risk of AD dementia.
- Results Reduced OI was associated with lower cognitive score and older age, as well as increased ratios of CSF t-tau and P 181 -tau to Aβ 1-42 (all p 1-42 alone except in APOE ε4 carriers having lowest-quartile Aβ 1-42 levels.
- Conclusions These findings from healthy high-risk older individuals suggest that OI reflects degree of preclinical AD pathology, while its relationships with age and cognition result from the association of these latter variables with such pathology.
Why it matters
In cognitively normal older adults with a family history of Alzheimer's dementia, poorer ability to identify odors was associated with lower cognitive scores and with higher ratios of CSF tau to amyloid-beta. This cross-sectional finding suggests odor identification might reflect preclinical Alzheimer's pathology, but it does not show that testing smell can prevent or treat the disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcross-sectional
- Participants101
- Evidence strengthModerate
How this study scored 62/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 101 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 146 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.3 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 4 / 6 | Cited 11.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author John C.S. Breitner: h-index 93 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28659431) |
| Free to read | 2 / 2 | Free to read |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Genetics from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.